FDA accepted Replimune’s resubmitted Biologics License Application for RP1 combined with Bristol Myers Squibb’s Opdivo to treat advanced melanoma The agency set April 10, 2026 as the decision deadline ...

Replimune Group is focused on developing immunotherapies using oncolytic viruses—engineered viruses that target and kill cancer cells while stimulating a patient’s immune response. Its lead product ...

Shares of Replimune (NASDAQ:REPL) plunged ~38% in the premarket on Monday after Stat News reported that the FDA’s top regulator of cancer drugs intervened during the review of the company’s lead asset ...

Despite a sharp drop in the previous session following the FDA rejection of its skin cancer drug RP1, Replimune (NASDAQ:REPL) shares bounced back on Wednesday even as multiple Wall Street analysts ...

Replimune Group, Inc. (NASDAQ:REPL) stock plunged on Tuesday after a U.S. Food and Drug Administration (FDA) update. The clinical stage biotechnology company received an FDA Complete Response Letter ...

Multiple analysts have issued price targets for $REPL recently. We have seen 4 analysts offer price targets for $REPL in the last 6 months, with a median target of ...

So, you’re wondering, “can I learn JavaScript in a day?” It’s a common question, and honestly, it’s a bit tricky. Think of it like this: can you learn to play the guitar in a day? You might learn a ...

Can a 3D Minecraft implementation be done entirely in CSS and HTML, without a single line of JavaScript in sight? The answer is yes! True, this small clone is limited to playing with blocks in a world ...

Since October 2024, Microsoft Defender Experts (DEX) has observed and helped multiple customers address campaigns leveraging Node.js to deliver malware and other payloads that ultimately lead to ...

Robbie has been an avid gamer for well over 20 years. During that time, he's watched countless franchises rise and fall. He's a big RPG fan but dabbles in a little bit of everything. Writing about ...